Cargando…

COPD treatment choices based on blood eosinophils: are we there yet?

Eosinophils are increasingly being recognised as an important characteristic feature of COPD. Patients with COPD and eosinophilic inflammation tend to respond to steroid therapy; however, many questions remain regarding the optimum measurement. Eosinophilic inflammation may be defined based on vario...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliver, Brian, Tonga, Katrina, Darley, David, Rutting, Sandra, Zhang, Xin, Chen, Hui, Wang, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885347/ https://www.ncbi.nlm.nih.gov/pubmed/31803266 http://dx.doi.org/10.1183/20734735.0254-2019

Ejemplares similares

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2018)

Airway smooth muscle cells from severe asthma patients with fixed airflow obstruction are responsive to steroid and bronchodilator treatment in vitro
por: Rutting, Sandra, et al.
Publicado: (2021)

Fixed Airflow Obstruction in Asthma: A Problem of the Whole Lung Not of Just the Airways
por: Rutting, Sandra, et al.
Publicado: (2022)

Heightened response to e-cigarettes in COPD
por: Bozier, Jack, et al.
Publicado: (2019)

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
por: Singh, Dave, et al.
Publicado: (2020)

Blood Eosinophils and Pulmonary Rehabilitation in COPD
por: Aljazeeri, Jafar, et al.
Publicado: (2021)

Variability of blood eosinophil count and prognosis of COPD exacerbations
por: Martínez-Gestoso, Sandra, et al.
Publicado: (2021)

Blood eosinophil count predicts treatment failure and hospital readmission for COPD
por: Kerkhof, Marjan, et al.
Publicado: (2020)

Are we there yet?
por: Wise, Jo Ann
Publicado: (2015)

Are we there yet?
por: Swann, Nicole
Publicado: (2019)

Are we there yet?
por: McCann, Shaun R.
Publicado: (2022)

Safe Nanoparticles: Are We There Yet?
por: Najahi-Missaoui, Wided, et al.
Publicado: (2020)

Sexually dimorphic production of interleukin‐6 in respiratory disease
por: Reddy, Karosham D., et al.
Publicado: (2020)

Higher body mass index is associated with increased lung stiffness and less airway obstruction in individuals with asthma and fixed airflow obstruction
por: Rutting, Sandra, et al.
Publicado: (2021)

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
por: Vogelmeier, Claus F., et al.
Publicado: (2019)

Biomarkers for SUDEP: Are We There Yet?
por: King-Stephens, David
Publicado: (2019)

Are we nearly there yet?
por: Battersby, Stephen
Publicado: (2005)

Why Are We Not There Yet?
por: Wenger, Nanette K.
Publicado: (2021)

Blood eosinophil count as a prognostic biomarker in COPD
por: Oh, Yeon-Mok, et al.
Publicado: (2018)

Blood and sputum eosinophils in COPD; relationship with bacterial load
por: Kolsum, Umme, et al.
Publicado: (2017)

Association between blood eosinophil count and small airway eosinophils in smokers with and without COPD
por: Maetani, Tomoki, et al.
Publicado: (2023)

“Are We There Yet?” Quest for Treatment of Refractory Epilepsy
por: Velíšek, Libor
Publicado: (2019)

Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
por: Griñan-Lison, Carmen, et al.
Publicado: (2021)

Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?
por: Vass, Caroline M., et al.
Publicado: (2017)

Blood eosinophil level to predict chronic obstructive pulmonary disease clinical outcomes: not ready yet
por: Cai, Cheng-Sen, et al.
Publicado: (2019)

Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO
por: Camp, James, et al.
Publicado: (2018)

Effectiveness of Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease Therapy: Focusing on Traditional Medical Practices
por: Tonga, Katrina O., et al.
Publicado: (2023)

Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
por: Thomas, Oliver S., et al.
Publicado: (2019)

Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients
por: Prudente, Robson, et al.
Publicado: (2021)

Humanized mice: are we there yet?
por: Macchiarini, Francesca, et al.
Publicado: (2005)

Cancer vaccines: Are we there yet?
por: Hanna, Jr., Michael G.
Publicado: (2012)

Cancer immunotherapy: are we there yet?
por: Li, Zihai, et al.
Publicado: (2013)

Myocardial Inflammation—Are We There Yet?
por: Greulich, Simon, et al.
Publicado: (2015)

The Artificial Pancreas: Are We There Yet?
por: Cefalu, William T., et al.
Publicado: (2014)

Regenerative medicine: are we there yet?
por: Badylak, Stephen, et al.
Publicado: (2017)

Peak MSC—Are We There Yet?
por: Olsen, Timothy R., et al.
Publicado: (2018)

Dracunculiasis Eradication: Are We There Yet?
por: Hopkins, Donald R., et al.
Publicado: (2018)

Robotics and ophthalmology: Are we there yet?
por: Pandey, Suresh K, et al.
Publicado: (2019)

Precision Oncology: Are We There Yet?
Publicado: (2017)

Dietary ω-6 polyunsaturated fatty acid arachidonic acid increases inflammation, but inhibits ECM protein expression in COPD
por: Rutting, Sandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uh1fgtnjsu6vj096gphrgc1e16